In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of the Blog: IN VIVO, February 2008

Executive Summary

Best of the Blog is a monthly column highlighting the best of our online content at In February, Windhover's staff posted 52 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory, and commercial news.

You may also be interested in...

Prasugrel and Wall Street: Lilly Tries to Stop the Bleeding

Lilly is in a race against the clock: it is counting on prasugrel to carve out a blockbuster position in the anti-clotting market before 2011. That is when Plavix generics will complicate the anti-clotting marketand Zyprexa generics will complicate Lilly's outlook. But will FDA go along with Lilly's schedule?

The Data Everybody's Talking About: Proof FDA is More Conservative?

Approval letters are down, "approvable" and "non-approvable" letters are up. "Black box" warnings have seen a four-fold increase over the last five years. Biopharma executives are now drawing their own conclusions about the state of FDA regulation-based on the numbers.

Can Amgen Find a New Engine?

Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts